Ranger Investment Management L.P. Has $34.32 Million Stake in ADMA Biologics Inc $ADMA

Ranger Investment Management L.P. lessened its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 2.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,340,730 shares of the biotechnology company’s stock after selling 49,645 shares during the quarter. ADMA Biologics comprises about 2.4% of Ranger Investment Management L.P.’s investment portfolio, making the stock its 5th biggest holding. Ranger Investment Management L.P. owned 0.98% of ADMA Biologics worth $34,315,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Thrivent Financial for Lutherans increased its position in shares of ADMA Biologics by 78.1% during the 2nd quarter. Thrivent Financial for Lutherans now owns 3,315,425 shares of the biotechnology company’s stock valued at $60,373,000 after purchasing an additional 1,453,924 shares during the period. Franklin Resources Inc. boosted its stake in ADMA Biologics by 66.4% during the second quarter. Franklin Resources Inc. now owns 2,719,016 shares of the biotechnology company’s stock valued at $49,513,000 after buying an additional 1,085,286 shares in the last quarter. First Light Asset Management LLC acquired a new position in ADMA Biologics during the second quarter worth about $17,338,000. State Street Corp raised its position in ADMA Biologics by 5.6% in the second quarter. State Street Corp now owns 12,078,505 shares of the biotechnology company’s stock worth $219,950,000 after acquiring an additional 637,727 shares in the last quarter. Finally, Balyasny Asset Management L.P. lifted its holdings in ADMA Biologics by 154.5% in the 2nd quarter. Balyasny Asset Management L.P. now owns 971,414 shares of the biotechnology company’s stock valued at $17,689,000 after acquiring an additional 589,707 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, ADMA Biologics has an average rating of “Buy” and a consensus price target of $28.50.

ADMA Biologics Stock Up 2.6%

Shares of ADMA Biologics stock opened at $16.35 on Friday. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67. The firm has a market capitalization of $3.89 billion, a PE ratio of 19.01 and a beta of 0.49. The company has a quick ratio of 3.65, a current ratio of 7.13 and a debt-to-equity ratio of 0.18. The stock’s fifty day moving average is $18.40 and its 200-day moving average is $17.02.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.16. The firm had revenue of $134.22 million for the quarter, compared to analysts’ expectations of $131.20 million. ADMA Biologics had a return on equity of 36.52% and a net margin of 42.87%.ADMA Biologics’s revenue was up 12.0% on a year-over-year basis. During the same quarter last year, the business posted $0.15 EPS. Equities analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.